Retrophin (RTRX) Reaches New 1-Year High and Low at $27.76

Retrophin Inc (NASDAQ:RTRX)’s share price reached a new 52-week high and low on Thursday . The company traded as low as $27.76 and last traded at $26.97, with a volume of 448501 shares. The stock had previously closed at $25.58.

RTRX has been the subject of a number of analyst reports. Zacks Investment Research raised Retrophin from a “strong sell” rating to a “hold” rating in a report on Thursday, January 4th. ValuEngine raised Retrophin from a “sell” rating to a “hold” rating in a report on Wednesday, March 7th. BidaskClub cut Retrophin from a “buy” rating to a “hold” rating in a report on Saturday, December 30th. Finally, BMO Capital Markets reduced their price target on Retrophin from $44.00 to $43.00 and set an “outperform” rating for the company in a report on Wednesday, April 4th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. Retrophin presently has a consensus rating of “Hold” and an average price target of $43.00.

How to Become a New Pot Stock Millionaire

The company has a quick ratio of 3.74, a current ratio of 3.80 and a debt-to-equity ratio of 0.15.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.20). Retrophin had a negative return on equity of 13.98% and a negative net margin of 38.55%. The firm had revenue of $42.18 million for the quarter, compared to analysts’ expectations of $42.20 million. equities analysts anticipate that Retrophin Inc will post -1.6 EPS for the current year.

A number of large investors have recently bought and sold shares of RTRX. Consonance Capital Management LP increased its stake in Retrophin by 4.0% during the 4th quarter. Consonance Capital Management LP now owns 3,644,438 shares of the biopharmaceutical company’s stock worth $76,788,000 after buying an additional 138,834 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Retrophin by 8.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 896,815 shares of the biopharmaceutical company’s stock worth $22,322,000 after buying an additional 71,562 shares in the last quarter. Bank of Montreal Can increased its stake in Retrophin by 51.5% during the 4th quarter. Bank of Montreal Can now owns 181,416 shares of the biopharmaceutical company’s stock worth $3,823,000 after buying an additional 61,634 shares in the last quarter. GW&K Investment Management LLC increased its stake in Retrophin by 40.7% during the 4th quarter. GW&K Investment Management LLC now owns 190,545 shares of the biopharmaceutical company’s stock worth $4,015,000 after buying an additional 55,130 shares in the last quarter. Finally, Virtus Fund Advisers LLC purchased a new stake in Retrophin during the 4th quarter worth approximately $933,000.

WARNING: This article was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.thelincolnianonline.com/2018/04/14/retrophin-rtrx-reaches-new-1-year-high-and-low-at-27-76.html.

Retrophin Company Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply